Good morning, everyone, and how are you today? We are just fine, thank you, especially since the short person has recovered and made the dash to the local schoolhouse on time. The official mascots, meanwhile, are again happily snoozing, and we are enjoying another cup of stimulation. The neurons need some help more often than not. As for you, here are some tidbits to help you along. Hope your day goes well and do stay in touch …
Three Pfizer executives will still receive $1 million cash awards tied to the failed merger with Allergan, even though the deal was terminated, Bloomberg News tells us. John Young, group president of global established pharma business, and Mikael Dolsten, president of global R&D, were granted retention awards. And Albert Bourla, who was just promoted to head of global innovative pharma business, is also getting a $1 million reward.
Valeant Pharmaceuticals won a commitment from most of its lenders to amend terms of its debt, according to the Wall Street Journal. Meanwhile, Bill Ackman, whose Pershing Square Holdings has a big stake in the drug maker and who has a seat on the board, says financial statements are on track to be filed with regulators by the end of the month and a new chief executive will be named in weeks, not months, Reuters reports.
About the Author Reprints
